AKT1 and breast cancer: Importantly, blocking PI3K–AKT signaling, a pathway frequently dysregulated across various breast cancer subtypes [38, 39], strikingly diminished the tumor-promoting effect of ADSCs (Fig. 6), underscoring the predominant role of this oncogenic pathway in tumor formation and progression.